RVP Retractable Technologies (RVP) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000946563
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
Retractable Technologies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for RETRACTABLE TECHNOLOGIES INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 194 earlier Form 4 trades (code P or S) here by this insider (194 buys), the last on Nov 11, 2025.
- +2.5% median (+3.3% mean) 90-day return after 30 previous buys.
- The trade is 0.0% of the 15,831,222 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO SHAW THOMAS J bought about $4.4K of RVP on Nov 14, 2025; 9 funds added in the latest 13F quarter.Context
- 193 earlier Form 4 trades (code P or S) here by this insider (193 buys), the last on Nov 5, 2025.
- +3.1% median (+4.9% mean) 90-day return after 30 previous buys.
- The trade is 0.0% of the 15,825,491 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO SHAW THOMAS J bought about $81 of RVP on Nov 11, 2025; 9 funds added in the latest 13F quarter.Context
- 192 earlier Form 4 trades (code P or S) here by this insider (192 buys), the last on Oct 30, 2025.
- +3.8% median (+6.5% mean) 90-day return after 30 previous buys.
- The trade is 0.0% of the 15,825,391 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO SHAW THOMAS J bought about $6.2K of RVP on Nov 5, 2025; 9 funds added in the latest 13F quarter.Context
- 191 earlier Form 4 trades (code P or S) here by this insider (191 buys), the last on Oct 28, 2025.
- +4.4% median (+7.7% mean) 90-day return after 30 previous buys.
- The trade is 0.1% of the 15,817,891 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO SHAW THOMAS J bought about $12.9K of RVP on Oct 30, 2025; 9 funds added in the latest 13F quarter.Context
- 190 earlier Form 4 trades (code P or S) here by this insider (190 buys), the last on Oct 27, 2025.
- +5.7% median (+9.0% mean) 90-day return after 30 previous buys.
- The trade is 0.2% of the 15,802,891 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO SHAW THOMAS J bought about $32.2K of RVP on Oct 28, 2025; 9 funds added in the latest 13F quarter.213 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Medical Devices
Revenue
+15.8% year over year
more than 63% of Medical Devices
Margin
-32.8% net margin
below 61% of Medical Devices
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 86% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch RVP
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-38.9%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RVP: institutional holders (13F)
13F holdings, latest reported quarter
581,736 sh
$418.9K
580,919 sh
$418.3K
441,407 sh
$317.8K
241,121 sh
$173.6K
121,005 sh
$87.1K
Congress trades in RVP
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RVP planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
RVP mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$46.2K position · as of 2026-06-30
0.0%
Omni Small-Cap Value Fund
$6.8K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$54.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$122.1K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$21.7K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$296.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.2M
$1.2M
$304.3K
-93%
+15%
2024
$1.2M
$1.2M
$279.3K
-93%
+7%
2023
$1.1M
$1.1M
$280.5K
-90%
-1%
2022
$1.1M
$8.6M
$276.4K
-85%
-3%
2021
$11.5M
$4.0M
$1.3M
-35%
+21%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
RVP financials
Revenue growth
+15.8%
XBRL, annual
Net margin
-32.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$33.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RVP
| FY Dec 2025 | $38.3M |
| FY Dec 2024 | $33.0M |
| FY Dec 2023 | $43.6M |
| FY Dec 2022 | $94.8M |
| FY Dec 2021 | $188.4M |
| Jun 2026 | $7.2M |
| Mar 2026 | $7.2M |
| Dec 2025 | $9.4M |
| Sep 2025 | $10.1M |
| Jun 2025 | $10.4M |
| Mar 2025 | $8.3M |
| Dec 2024 | $9.1M |
| Sep 2024 | $10.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-9.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RVP
| FY Dec 2025 | -32.8% |
| FY Dec 2024 | -36.0% |
| FY Dec 2023 | -16.1% |
| FY Dec 2022 | +5.4% |
| FY Dec 2021 | +29.8% |
| Jun 2026 | +39.3% |
| Mar 2026 | -58.9% |
| Dec 2025 | -24.9% |
| Sep 2025 | +3.7% |
| Jun 2025 | -0.8% |
| Mar 2025 | -126.6% |
| Dec 2024 | +41.6% |
| Sep 2024 | -18.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM RVP
| FY Dec 2025 | -$7.9M |
| FY Dec 2024 | -$13.0M |
| FY Dec 2023 | $1.9M |
| FY Dec 2022 | -$61.9K |
| FY Dec 2021 | -$25.6M |
| Jun 2026 | -$1.8M |
| Mar 2026 | -$1.4M |
| Dec 2025 | n/a |
| Sep 2025 | -$1.3M |
| Jun 2025 | -$4.1M |
| Mar 2025 | -$1.6M |
| Dec 2024 | -$1.4M |
| Sep 2024 | -$6.5M |
At each fiscal year end
Single quarter
Debt to equity
0.01x
LongTermDebt as filed 2025-12-31 (6 months older than the period end) (includes the current portion); equity 2026-06-30
Debt to equity RVP
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | 0.02x |
| FY Dec 2022 | 0.02x |
| FY Dec 2021 | 0.02x |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.01x |
| Jun 2025 | 0.01x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-5.53x
TTM operating cash flow over LongTermDebt as filed 2025-12-31 (6 months older than the period end) (includes the current portion)
Cash flow to debt RVP
| FY Dec 2025 | -7.89x |
| FY Dec 2024 | -9.38x |
| FY Dec 2023 | 1.80x |
| FY Dec 2022 | 9.22x |
| FY Dec 2021 | 15.59x |
| Jun 2026 | -5.53x |
| Mar 2026 | -7.77x |
| Dec 2025 | -7.89x |
| Sep 2025 | -7.71x |
| Jun 2025 | -11.28x |
| Mar 2025 | -9.57x |
| Dec 2024 | -9.38x |
| Sep 2024 | -6.52x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-4.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity RVP
| FY Dec 2025 | -15.6% |
| FY Dec 2024 | -12.7% |
| FY Dec 2023 | -6.8% |
| FY Dec 2022 | +4.9% |
| FY Dec 2021 | +75.2% |
| Jun 2026 | -4.5% |
| Mar 2026 | -8.6% |
| Dec 2025 | -15.6% |
| Sep 2025 | -8.0% |
| Jun 2025 | -10.8% |
| Mar 2025 | -25.9% |
| Dec 2024 | -12.7% |
| Sep 2024 | -17.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-2.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RVP
| FY Dec 2025 | -8.3% |
| FY Dec 2024 | -7.0% |
| FY Dec 2023 | -3.7% |
| FY Dec 2022 | +2.5% |
| FY Dec 2021 | +36.0% |
| Jun 2026 | -2.3% |
| Mar 2026 | -4.4% |
| Dec 2025 | -8.3% |
| Sep 2025 | -4.2% |
| Jun 2025 | -5.7% |
| Mar 2025 | -14.0% |
| Dec 2024 | -7.0% |
| Sep 2024 | -9.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital RVP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1.0% |
| FY Dec 2021 | +102.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-17.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RVP
| FY Dec 2025 | -14.9% |
| FY Dec 2024 | -13.1% |
| FY Dec 2023 | -6.5% |
| FY Dec 2022 | -0.5% |
| FY Dec 2021 | +58.5% |
| Jun 2026 | -17.0% |
| Mar 2026 | -17.0% |
| Dec 2025 | -14.9% |
| Sep 2025 | -14.4% |
| Jun 2025 | -15.2% |
| Mar 2025 | -14.8% |
| Dec 2024 | -13.1% |
| Sep 2024 | -10.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing RVP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 10.93x |
| FY Dec 2021 | 4.25x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$15.6M
market value at close 2026-10-26 on 2026-08-01 shares, plus LongTermDebt as filed 2025-12-31 (6 months older than the period end) (includes the current portion), minus cash 2026-06-30
Enterprise value RVP
| FY Dec 2025 | $21.4M |
| FY Dec 2024 | $17.7M |
| FY Dec 2023 | $22.1M |
| FY Dec 2022 | $36.1M |
| FY Dec 2021 | $206.9M |
| Jun 2026 | $19.8M |
| Mar 2026 | $17.9M |
| Dec 2025 | $21.4M |
| Sep 2025 | $22.7M |
| Jun 2025 | $17.2M |
| Mar 2025 | $18.7M |
| Dec 2024 | $17.7M |
| Sep 2024 | $20.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield RVP
| FY Dec 2025 | -34.1% |
| FY Dec 2024 | -62.9% |
| FY Dec 2023 | +5.8% |
| FY Dec 2022 | -0.1% |
| FY Dec 2021 | -10.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -34.1% |
| Sep 2025 | -33.3% |
| Jun 2025 | -70.7% |
| Mar 2025 | -58.7% |
| Dec 2024 | -62.9% |
| Sep 2024 | -42.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing RVP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.04x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $38.3M | $33.0M | $43.6M | $94.8M |
| Gross profit | $47.0K | -$1.0M | $9.1M | $28.3M |
| Operating income | -$21.2M | -$21.1M | -$11.5M | -$853.0K |
| Net income | -$12.6M | -$11.9M | -$7.0M | $5.1M |
| EPS (diluted) | -0.43 | -0.40 | -0.24 | 0.15 |
| Operating cash flow | -$7.1M | -$11.6M | $2.8M | $16.8M |
| Cash | $2.6M | $4.2M | $12.7M | $19.7M |
| Long-term debt | $895.6K | $900.0K | $1.2M | $1.5M |
| Buybacks | n/a | n/a | n/a | $7.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
RVP Stock Sonar score 5/7 axes
Find similar shapesCompareRVP ranks highest on risk and compliance (70th percentile) and growth (63rd), and lowest on institutional and government (14th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
